Can blood transfer can somehow help a case of scleroderma?

I know it's not the way to cure it, but I was just wondering if this can slow down the body destruction made by the faulty lymphocytes.

Please answer in plain English, but still backed up by reliable references.

  • 1
    It is ok to offer a bounty on this question, however the wording inviting speculation is against site policy. You may reinstate the bounty without requesting speculation.
    – JohnP
    Feb 5, 2016 at 15:07
  • @JohnP, Thank you - I didn't know. In general, I agree that speculation can be just unwanted noise, but I believe that speculation is better than nothing when named. Every proof starts from just idea. If there is no proof, ideas is all we have. Shouldn't we share it then? Feb 6, 2016 at 9:36
  • 1
    Hi @MichałŠrajer, some may agree with that, but so far, this site has been about proven facts, or supported statements. We want to keep this site informative, not one filled with unproven claims, so we keep a strict policy. Thanks for understanding!
    – Dave Liu
    Feb 8, 2016 at 0:59
  • @DaveL, Sure, It's this community rules. I respect that. Feb 8, 2016 at 10:42

1 Answer 1


I'm not aware of any work done in this area. A whole blood transfusion is not going replace circulating defective lymphocytes.

On the other hand Hematopoietic Stem Cell Transplantation has some promise in patients with deteriorating lung function.

Autologous HSCT could “reset” the host immune system to a point in time when the antigenic triggers of autoimmunity were not present (41). Illustrative of this point, is the fact that pre-HSCT immunity wanes and often disappears after autologous HSCT. In recipients of TBI conditioning and autologous HSCT, the T-cell receptor (TCR) repertoire diversity was shown to normalize after lymphoablation and autologous transplant (42).


But do the benefits of autologous HSCT outweigh the risks? Likely not in autoimmune diseases with low associated mortality, but for scleroderma lung disease the benefits appear compelling. Replicated in multiple phase II reports from Europe and the US, dramatic and durable improvements in skin fibrosis and quality of life measures have been observed along with stabilization of PFTs. Three prospective, randomized clinical trials in patients with SSc and internal organ involvement have compared autologous HSCT treatment to high-dose IV pulse CYC given for up to 12 months. The SCOT trial is still following all subjects through the 54th month primary endpoint, but as detailed above the ASSIST and ASTIS randomized trials have been completed and both report statistically significant clinical benefits after stem cell transplantation.


Your Answer

By clicking “Post Your Answer”, you agree to our terms of service, privacy policy and cookie policy

Not the answer you're looking for? Browse other questions tagged or ask your own question.